Gemzar News and Research

RSS
Teva, APP enter agreement for launch of generic Gemzar

Teva, APP enter agreement for launch of generic Gemzar

Infinity provides guidance on anticipated pipeline and business goals for 2011

Infinity provides guidance on anticipated pipeline and business goals for 2011

Infinity extends global strategic alliance with Mundipharma for development, commercialization of IPI-926

Infinity extends global strategic alliance with Mundipharma for development, commercialization of IPI-926

BioCancell raises $5.1 million by excess demand in public offering

BioCancell raises $5.1 million by excess demand in public offering

Infinity announces enrollment in IPI-926 Phase 1b/2 clinical trial for pancreatic cancer

Infinity announces enrollment in IPI-926 Phase 1b/2 clinical trial for pancreatic cancer

Hospira launches two-gram vial of gemcitabine hydrochloride for injection

Hospira launches two-gram vial of gemcitabine hydrochloride for injection

Infinity announces Phase 1b/2 clinical trial of IPI-926 in patients with metastatic pancreatic cancer

Infinity announces Phase 1b/2 clinical trial of IPI-926 in patients with metastatic pancreatic cancer

BioCancell reports results of BC-819 Phase I/IIa clinical trial for pancreatic cancer

BioCancell reports results of BC-819 Phase I/IIa clinical trial for pancreatic cancer

BioCancell's Phase I/IIa clinical trial of BC-819 shows positive result for pancreatic cancer

BioCancell's Phase I/IIa clinical trial of BC-819 shows positive result for pancreatic cancer

Infinity announces preliminary results of IPI-926 Phase 1 study in patients with solid tumors

Infinity announces preliminary results of IPI-926 Phase 1 study in patients with solid tumors

Genta commences new tesetaxel Phase 2 clinical trial in advanced bladder cancer

Genta commences new tesetaxel Phase 2 clinical trial in advanced bladder cancer

Infinity Pharmaceuticals to present IPI-926 inhibitor Phase 1 data at ESMO Congress

Infinity Pharmaceuticals to present IPI-926 inhibitor Phase 1 data at ESMO Congress

Array BioPharma fiscal 2010 revenue increases to $53.9 million

Array BioPharma fiscal 2010 revenue increases to $53.9 million

Infinity reports $18.4 million total revenue for second-quarter 2010

Infinity reports $18.4 million total revenue for second-quarter 2010

U.S. Court of Appeals rules against Eli Lily's claims in Gemzar patent lawsuit

U.S. Court of Appeals rules against Eli Lily's claims in Gemzar patent lawsuit

Eli Lilly disagrees with U.S. Court of Appeals ruling on Gemzar method-of-use patent

Eli Lilly disagrees with U.S. Court of Appeals ruling on Gemzar method-of-use patent

Study results show no improvement in overall survival for combination of gemcitabine and Amplimexon

Study results show no improvement in overall survival for combination of gemcitabine and Amplimexon

CTRC starts enrolment in Phase 2 combination trial of REOLYSIN and gemcitabine for advanced pancreatic cancer

CTRC starts enrolment in Phase 2 combination trial of REOLYSIN and gemcitabine for advanced pancreatic cancer

Data evaluating use of nab-paclitaxel for treatment of pancreatic cancer to be presented at ASCO 2010

Data evaluating use of nab-paclitaxel for treatment of pancreatic cancer to be presented at ASCO 2010

Array BioPharma reports 18.4M revenue for third-quarter fiscal 2010

Array BioPharma reports 18.4M revenue for third-quarter fiscal 2010